A Phase 3 interventional study of D-2570 Tablet and BMS-986165 Tablet in Plaque Psoriasis, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by InventisBio Co., Ltd · Phase 3, Interventional, and Treatment
This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.
Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period.
During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.
2,028 studies on the registry are indexed under Psoriasis; 275 are open to participants now.
This study's planned enrollment of 477 is above the median of 75 across 1,565 interventional studies indexed under Psoriasis.
Browse Psoriasis studies →InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: D-2570 Tablet · Drug: Placebo
Drug: D-2570 Tablet · Drug: BMS-986165 Tablet
Drug: D-2570 Tablet
Drug: D-2570 Tablet
D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain
BMS-986165 is a novel inhibitor targeting TYK2
A placebo refers to a tablet that has no therapeutic effect on medication
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis
Psoriasis Area and Severity Index (PASI)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis
Physician Global Assessment (PGA)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the efficacy of different doses of D-2570 compared with placebo in the treatment of patients with moderate to severe plaque psoriasis
Dermatology Life Quality Index (DLQI)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the efficacy of different doses of D-2570 compared with BMS-986165 in the treatment of patients with moderate to severe plaque psoriasis
Psoriasis Area and Severity Index (PASI)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the efficacy of different doses of D-2570 compared with BMS-986165 in the treatment of patients with moderate to severe plaque psoriasis
Physician Global Assessment (PGA)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the efficacy of different doses of D-2570 compared with BMS-986165 in the treatment of patients with moderate to severe plaque psoriasis
Dermatology Life Quality Index (DLQI)
Time frame: Treatment for 16 weeks after enrollment
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Vital signs: blood pressure
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Vital signs: body temperature
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Vital signs: heart rate
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Vital signs: respiration
Time frame: Through study completion, an average of 28 weeks
To evaluate the physical examination of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
12-lead electrocardiogram (ECG) examination: QT Interval
Time frame: Through study completion, an average of 28 weeks
To evaluate the safety of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
12-lead electrocardiogram (ECG) examination: Heart rate
Time frame: Through study completion, an average of 28 weeks
To evaluate the pharmacokinetic characteristics (PK) of different doses of D-2570 in the treatment of patients with moderate to severe plaque psoriasis
Blood drug concentration
Time frame: Day1, Day15, Day29, Day57, Day85, Day113
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 18 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570